Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA MDUFA III Performance, By The Numbers

This article was originally published in The Gray Sheet

Executive Summary

Here's a snapshot of FDA's current premarket device review activity in seven interactive graphics.


Related Content

Bringing Private Payers To The Regulatory Table: FDA Reaches Out To Insurers
FDA Hits User-Fee-Era Record For 'Novel' Devices: A New Normal?
Top 15 In '15: The Most-Read "Gray Sheet" Stories Of The Year
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
FDA Tries To Get 'Smart' In Standardizing 510(k) Reviews
PMA Approvals On Track For 15-Year High
Calls For More FDA Training In Lead Up To User-Fee Negotiations
Successful De Novo Petitions Double With Advent Of Direct Route
FDA Reports Declining 510(k) Times, And Other Improvements
FDA Addresses Pre-Submission Meetings In Draft Guidance





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts